Missouri is currently home to 1898 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Membrane Target Detection for Leukemia Treatment
NCT04841447
Recruiting
Acute myeloid leukemia (AML) accounts for more than 40% of leukemia mortality in the United States. Each year around ten thousand people die from the disease, most within a few years of diagnosis. Despite advances in our understanding of the disease, few improvements in the therapy of AML have been made. Collecting specimens from the blood and bone marrow will increase understanding of the effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors on human AML-SCP to develop individualized therapies. W... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/03/2024
Locations: University of Missouri, Columbia, Missouri
Conditions: Hematological Malignancy
Register for Updates
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
NCT02074839
Recruiting
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where four cohorts of pati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/03/2024
Locations: Washington University, Saint Louis, Missouri
Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic Syndromes
Register for Updates
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
NCT04742634
Recruiting
The investigators hypothesize that early measurable residual disease (MRD)-guided pre-emptive therapy with decitabine + cedazaridine (DEC-C) will decrease the risk of progression in post-transplant myelodysplastic syndromes (MDS) patients with persistent mutations (molecular MRD). To detect molecular MRD, the investigators will perform ultra-deep, error-corrected panel-based sequencing (MyeloSeq-HD) at Day 30 in post-transplant MDS patients. The investigators will treat patients with detectable... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/02/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Myelodysplastic Syndromes
Register for Updates
The PROTEMBO Trial
NCT05873816
Recruiting
The goal of this prospective, multi-center, randomized, controlled study is to compare the safety and efficacy of the ProtEmbo Cerebral Embolic Protection device to a hybrid control (no embolic protection device ('No Device') and the Sentinel device) in subjects with severe symptomatic native aortic valve stenosis indicated undergoing a TAVR procedure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/30/2024
Locations: Saint Luke's Hospital of Kansas City, Kansas City, Missouri
Conditions: Severe Aortic Valve Stenosis
Register for Updates
Epidemiology of Silent and Overt Strokes in Sickle Cell Disease
NCT03376893
Recruiting
Sickle Cell Disease (SCD) is a rare disease occurring in an estimated 100,000 individuals, often poor and underserved, in the US. Silent and overt strokes contribute significantly to morbidity in adults with SCD, resulting in functional impairment, challenges with school and job performance, and premature death. Five NIH-funded randomized controlled trials have identified therapies to prevent silent and overt strokes in children with SCD, including monthly blood transfusion therapy (for preventi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/30/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Anemia, Sickle Cell, Sickle Cell Disease, Stroke, Sickle Cell Thalassemia, Sickle Cell-Beta0-Thalassemia
Register for Updates
Safety Study of PP-007 in Subjects With Acute Ischemic Stroke
NCT04677777
Recruiting
The HEMERA-1 Extension (Part III) is a prospective, open-label, multicenter study to evaluate safety of two doses of PP-007 in Acute Ischemic Stroke (AIS) subjects receiving Intravenous Thrombolysis (IVT) or mechanical thrombectomy (MT) or IVT+MT as standard of care (SOC). Subjects will receive two doses of PP-007 infusion 24 ± 6 hours apart in addition to the site-specific SOC protocol. PP-007 is PEGylated bovine carboxyhemoglobin and will be administered via IV infusion. The effects on collate... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/28/2024
Locations: Saint Luke's Hospital, Kansas City, Missouri
Conditions: Acute Ischemic Stroke
Register for Updates
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
NCT05643742
Recruiting
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Research Site, Saint Louis, Missouri
Conditions: B-cell Lymphoma, Non-hodgkin Lymphoma, B-cell Malignancy, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Register for Updates
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
NCT04756726
Recruiting
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cemsidomide may be administered as a single agent and, in MM only, in combination with oral dexamethasone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Washington University School of St. Louis, Saint Louis, Missouri
Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin's
Register for Updates
The APS Phenotyping Study
NCT06521502
Recruiting
The goal of the observational APS phenotyping study is to better understand risk factors, potential biomarkers, length and severity of illness, and recovery for adults with ARDS, pneumonia, and/ or sepsis. This study will also generate a biobank of specimens collected from these patients that will be available to investigators for future studies of ARDS, sepsis, and/or pneumonia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: ARDS, Sepsis, Pneumonia
Register for Updates
Tied Tube Trial in Glaucoma Surgery
NCT05685485
Recruiting
The aim of this study is to assess whether delaying early flow through the Ahmed tube shunt may improve the post-operative surgical outcomes and provide a more predictable outcome. To assess this the investigator will conduct a, randomized prospective, multi-centered study with collaborators at WashU in St. Louis, Duke University, Indiana University and the University of Pittsburgh. Participants will be randomized to have an AGV placement with tube ligation (no-early flow) and without ligation (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2024
Locations: Washington University, Saint Louis, Missouri
Conditions: Glaucoma Eye, Ahmed Glaucoma Valve Implantation
Register for Updates
Intraamniotic Administrations of ER004 to Male Subjects With X-linked Hypohidrotic Ectodermal Dysplasia
NCT04980638
Recruiting
This is an open-label, prospective, genotype-match controlled for primary estimand, non randomized, multicenter, international Phase 2 clinical trial designed to investigate the efficacy and safety of ER004 administered intraamniotically as a treatment for unborn XLHED male subjects.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/26/2024
Locations: Washington University, Saint Louis, Missouri
Conditions: X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
Register for Updates
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
NCT04372615
Recruiting
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/26/2024
Locations: Washington University in St. Louis School of Medicine, Saint Louis, Missouri
Conditions: Autoimmune Encephalitis, Encephalitis
Register for Updates